{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-090311","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.616707+00:00","generated_at":"2026-05-31T13:07:14.305500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome Q2 revenue $87.2M (+87% YoY); Auvelity sales $65.0M (+135%)","bullets":["Total net product revenue $87.2M, up 87% YoY; Auvelity $65.0M (+135%), Sunosi $22.1M (+16%).","Net loss $79.3M ($1.67 per share) vs $67.2M ($1.54) in Q2 2023; cash $315.7M.","NDA for AXS-07 in migraine resubmitted; NDA submission for AXS-14 in fibromyalgia expected Q3 2024.","Patent litigation with Unichem settled; generic Sunosi entry allowed no earlier than June 30, 2042.","Anticipated topline results: AXS-05 (AD agitation), solriamfetol (ADHD), AXS-12 (narcolepsy) in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-090311","json":"https://secwatch.observer/filing/0000950170-24-090311.json","markdown":"https://secwatch.observer/filing/0000950170-24-090311.md","text":"https://secwatch.observer/filing/0000950170-24-090311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/0000950170-24-090311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024090311/axsm-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:07:14.305500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}